WASHINGTON -- The FDA has approved pimavanserin (Nuplazid) for the treatment of hallucinations and delusions associated with psychosis experienced by some people with Parkinson's disease, the agency announced Friday. Hallucinations or delusions can occur in as many as 50% of patients with Parkinson's disease at some time during the course of their illness, the FDA said in a press release.
If you find a dimension intereseting, we recommend you pick up one or two facts that you find intriguing and place them into your memory. That way you will have 2nd degree information about the topic if it comes up in conversation.
Accordingly, you can do the same with others as well.